Side-by-side comparison of AI visibility scores, market position, and capabilities
Cambridge MA YC W20 induced proximity medicines (molecular glues/PROTACs) targeting undruggable proteins; $16M Series A Jan 2025 Tomales Bay Capital competing with Arvinas and C4 Therapeutics for protein degradation oncology platform.
General Proximity is a Cambridge, Massachusetts-based biotechnology company — backed by Y Combinator (W20) with $16 million in Series A funding in January 2025 led by Tomales Bay Capital — pioneering induced proximity medicines that work by bringing together disease-causing proteins to trigger their degradation or modulation, representing a next-generation therapeutic modality beyond traditional small molecule inhibitors and biologics. Founded in 2020, General Proximity combines computational chemistry, medicinal chemistry, and structural biology to design molecular glues and PROTACs (proteolysis-targeting chimeras) for previously undruggable targets in oncology and other disease areas — targeting the protein degradation mechanisms that cells use naturally to eliminate aberrant proteins.
Mass spectrometry sample prep and data science platform delivering 100x productivity for biopharma protein analysis; $9.1M from Merck Digital Sciences Studio, NIH, and YC at $1.8M revenue.
Andson Biotech is an Atlanta-based healthcare technology company providing mass spectrometry solutions for biopharma and biomanufacturing — offering the DynaCHIP hardware system (a novel mass spectrometry sample preparation platform) and DynaMARK data science module that together deliver up to 100x productivity improvements in protein and biomolecule analysis workflows compared to conventional mass spectrometry setups. Backed by Y Combinator, Merck Digital Sciences Studio, and NIH with $9.1 million raised, Andson achieved $1.8 million in revenue as of December 2024.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.